424B3

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-184761

PROSPECTUS SUPPLEMENT NO. 17

(To Prospectus dated March 28, 2013)

592,000 Shares

Tengion, Inc.

This Prospectus Supplement No. 17 supplements the prospectus dated March 28, 2013 (as supplemented to date, the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-184761). The Prospectus and this prospectus supplement relate to the disposition from time to time of up to 592,000 shares of our common stock, which are held or may be held by the stockholders named in the Prospectus.

This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement. This prospectus supplement updates, amends and supplements the information included or incorporated by reference in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

Current Report on Form 8-K

On January 14, 2014, we filed a Current Report on Form 8-K with the Securities and Exchange Commission. The text of such Form 8-K is attached hereto.

Investing in our common stock involves a high degree of risk. Please see the section entitled “Risk Factors” beginning on page 22 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is January 14, 2014.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report(Date of earliest event reported):  January 13, 2014

Tengion, Inc.

(Exact name of registrant as specified in its charter)

001-34688

(Commission File Number)

Delaware	20-0214813
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation)

3929 Westpoint Blvd., Suite G

Winston-Salem, NC 27103

(Address of principal executive offices, with zip code)

(336) 722-5855

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

Beginning on January 13, 2014, Tengion, Inc. (the “Company”) intends to use the presentation furnished herewith, or portions thereof, in one or more meetings with investors and analysts. A copy of the presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this Item, including the exhibits attached hereto, are being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits

99.1 Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TENGION, INC.
Date:  January 14, 2014	By: /s/ A. Brian Davis
	A. Brian Davis
	Chief Financial Officer and Senior Vice President, Finance

Exhibit Index

Exhibit No.		Description
99.1	Investor Presentation

EX-99.1

 Corporate Presentation January 2014

Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to our future plans, objectives, expectations and intentions and may be identified by words like “believe,” “expect,” “designed,” “may,” “will,” “should,” “seek,” or “anticipate,” and similar expressions. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. Forward-looking statements are subject to risks and uncertainties. For instance, there can be no assurance that: (i) the Company will be able to successfully enroll patients in its clinical trials; (ii) patients enrolled in the Company's clinical trials will not experience adverse events related to the Company's product candidates, which could delay clinical trials or cause the Company to terminate the development of a product candidate; (iii) the results of the clinical trials for the Company’s product candidates will support further development or regulatory approval of such product candidates; (iv) the market opportunity data for the Neo-Urinary Conduit and the Neo-Kidney Augment, as well as the physician and payer feedback for the Neo-Urinary Conduit used by the Company, accurately predict the potential commercial opportunity for the Neo-Urinary Conduit and Neo-Kidney Augment, respectively; (v) the Company will be able to provide an efficient and scalable manufacturing process for any approved product; and (vi) the Company will be able enter into strategic partnerships on favorable terms, if at all, or obtain the capital it needs to develop its product candidates and continue its operations. For additional factors that could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements in this presentation are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this presentation.

Investment Highlights   •Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells •Neo-Kidney Augment: Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease   Two Phase 1 trials underway in chronic kidney disease patients in Sweden and U.S.   •Sweden: all 5 patients implanted in 2013; planned expansion from 5 to 15 patients   •To date, appears to be safe and well tolerated in 5 implanted patients   •U.S.: trial initiated late 2013 to implant up to 12 patients; anticipate completion of enrollment during 2014   •Neo-Urinary Conduit: Improve upon standard of care for bladder cancer patients requiring cystectomy (bladder removal)   §Anticipate completion of patient enrollment in Phase 1 open-label study   §Work with KOLs and FDA for guidance on next phase trials by mid-2014   •Focused on key value-creating milestones

Delivering Organ Regeneration for Patients Novel and proprietary technology platform: •Utilizes selected populations of regenerative cells •Potential to produce neo-organs at commercial scale •Potential for product line expansion Tissue biopsy Cell isolation and expansion Creation of product Implantation of neo-organ

Neo-Kidney Augment

Neo-Kidney Augment: Significant Market Opportunity  •~26 million adults in U.S. have CKD100,000 new dialysis patients each year350,000 currently on dialysis20% annual mortality$77,000 - annual cost per patient  •Worldwide shortage of organs for transplant$100,000 - cost of transplant in U.S.$30,000 - cost per patient per year for immunosuppression in U.S.

Neo-Kidney Augment Development Process Biopsy of kidney tissue Cell isolation and culture 2-3 weeks Cell selection <1 day Dose preparation 2 weeks Laparoscopic implantation

Neo-Kidney Augment Overview  •Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced CKD  •Robust preclinical data for Neo-Kidney Augment with defined mechanisms of action in CKD  •Efficient and scalable manufacturing process  •Ongoing clinical trials in Europe and U.S.

Summary of Animal Study for NKA: End-point and Timelines*  •NKA improved multiple systemic and histological measurements:Whole organism (Early effects ~ 3 months)Lowered mean arterial blood pressureTubular & interstitial function (Early to Mid-term effects 3-6 months):Improved protein handling: serum albumin, A/G ratioStabilized erythropoietic function: Hg, HctGlomerular (Late effects > 6 months):Stabilized filtration: serum creatinine, eGFRAttenuated progressive uremia: BUNBone mineralization (Late effects):Maintained calcitriol (Vit D) function: blood Phosphorous & Calcium  *= Kelley et al Cell Trans, 2013; Basu et al Cell Trans, 2011; Kelley et al Am J Phys/Renal Phys 2010; Presnell et al Tiss Eng 2010)

Neo-Kidney Augment: Patient Expansion Planned in Sweden Phase 1 Trial   •Phase 1 trial (Karolinska Institute in Stockholm, Sweden)Commenced in May 20135 patients implanted during 2013, planned expansion from 5 to 15 patients supported by DSMBEvaluate single pharmacologic dose and delivery in patientsWill follow each patient for up to two yearsData collected at 3, 6, 9 and 12 monthsTo date, appears to be safe and well tolerated in 5 implanted patients

Neo-Kidney Augment: Phase 1 Trial Recently Initiated in U.S.   •Phase 1 trial in U.S. currently enrolling under an open INDCommenced in November 2013Approved to enroll up to 12 patientsEvaluate single pharmacologic dose and delivery in patientsWill follow each patient for up to two yearsAnticipate completion of enrollment during 2014   •Continuing to work with multiple experts at top U.S. institutionsUNC-Chapel Hill, Duke, LSU, Vanderbilt, UCLA, Harvard

Neo-Urinary Conduit

Neo-Urinary Conduit: Large Market Opportunity   Estimated Urinary Diversion Surgical Procedures in 2012 *   13,100   15,200   *L.E.K. and company estimates   Number of procedures growing at ~3% per annum

Standard-of-Care for Urinary Diversion   Bladder removed   Section of bowel removed with blood supply maintained   Bowel placed into urinary tract between ureters and abdominal wall   Bowel connected to urine collection bag   Standard-of-Care   •Weeks to months of recovery time   •Use of bowel creates absorption challenges and can lead to metabolic disorders

Neo-Urinary Conduit: Establish New Standard of Care for Cystectomy   •Designed to establish new standard of care for bladder cancer patients undergoing cystectomy (removal of bladder)Eliminates need for bowel resection and urine absorption-related metabolic disorders70% of patients receiving current standard of care have co-morbidities   •Created using patient’s own cellsCells obtained from simple fat biopsyCells grown and placed on biodegradable scaffoldImplanted at time of cystectomy (removal of bladder)   •U.S. regulatory path: Biologics Licensing Application (BLA)

Advantages of Neo-Urinary Conduit   Neo-Urinary Conduit   Bladder removed   Conduit placed into urinary tract between ureters and abdominal wall   Conduit connected to urine collection bag   Advantages:   •Improved recovery times and faster hospital discharges   •No evidence to date of typical post-operative co-morbidities found with current standard of care

Neo-Urinary Conduit: Surgery and Regenerative Outcome   •Implantation with ureters and skin   •Regeneration of urinary tissue   Ureters   Urinary Conduit   Urinary Tissue   Omentum   Implanted   Neo-Urinary Conduit   Regenerated Conduit   Muco-Cutaneous   Junction

Neo-Urinary Conduit Phase 1 Clinical Trial   •Ongoing Phase 1 open-label study in up to 10 patients   •Goals of Phase 1 trial:Define surgical procedureTransfer to multiple clinical sitesDefine post-operative proceduresDemonstrate durable patient outcomes   •Patient 7 now one year post-implant, patient 8 implanted in early December 2013   •Investment by Celgene in 2013 is funding program through 2014   •Engage KOLs and FDA for guidance on next phase trials

Neo-Urinary Conduit Phase 1 Trial Progress: Defining Translation and Regeneration   •Insights gained from 8 patients implanted to date:Surgical procedure for a NUC implantation demonstrates urinary tissue regeneration in patients with bladder cancerEstablished initial post-operative care to optimize patency and durability of regenerated urinary tissue in patients with complex post-operative disease conditions   •Framework for defined surgical procedure and insights to post-op managementDefined the procedure (n=4)Repeated definitive procedure (n=4)Demonstrated SOC for complex conditions (metastatic cancer and polymicrobial chronic UTI; n=2)Clinical evidence of functional urinary tissue regeneration (n=4)

Positive Initial Payer Comments   •Believe $40,000 price for Neo-Urinary Conduit is reasonable   •Incremental cost savingsReduction in hospitalization timeReduction in complicationsQuality of life improvements   •Limited incremental exposure per payer   •Older population likely covered by Medicare   •Other autologous therapies have comparable prices   *Based on expected product profile

Corporate

Significant IP Protection   •Issued patent protection plus recent applications pending28 U.S. and 97 international patents and patent applicationsCore patents cover composition, design and methods of manufacture*8 issued and allowed patents in 2013   Plus know-how, trade secrets and integrated capabilities associated with the discovery, development and manufacturing of our product candidates   * Individual patents may cover multiple elements

Financial Overview  September 30, 2013 Cash and investments   Principal amount of   long-term debt   Adjusted net loss   $27.5 M   $35.9 M   $17.3 M   December 31, 2012   $7.7 M   $18.7 M   $18.9 M   $33.6M financing completed June 2013   Celgene Corporation   RA Capital   Deerfield Management   Bay City Capital   HealthCap   Perceptive Life Sciences   QVT Financial LP

Investment Highlights   •Biotechnology company with unique technology platform for tissue and organ regeneration using a patient’s own cells   •Neo-Kidney Augment: Intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney diseaseTwo Phase 1 trials underway in chronic kidney disease patients in Sweden and U.S.  •Sweden: all 5 patients implanted in 2013; planned expansion from 5 to 15 patients   •To date, appears to be safe and well tolerated in 5 implanted patients   •U.S.: trial initiated late 2013 to implant up to 12 patients; anticipate completion of enrollment during 2014   •Neo-Urinary Conduit: Improve upon standard of care for bladder cancer patients requiring cystectomy (bladder removal)Anticipate completion of patient enrollment in Phase 1 open-label studyWork with KOLs and FDA for guidance on next phase trials by mid-2014   •Focused on key value-creating milestones

Corporate Presentation January 2014